Drug Search Results
More Filters [+]

Plicamycin

Alternative Names: plicamycin, mithramycin, mithracin
Latest Update: 2022-04-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: RNA polymerase Inhibitor,RNA Synthesis Inhibitor,Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Greece | Ireland | New Zealand | South Africa

Approved Indications: None

Known Adverse Events: None

Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Plicamycin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Digestive System Cancer|Mesothelioma|Lung Cancer|Sarcoma, Ewing|Breast Cancer|Esophageal Cancer|Gastrointestinal Cancer|Sarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

16-C-0152

P2

Terminated

Sarcoma|Esophageal Cancer|Mesothelioma

2019-12-06

12-C-0151

P2

Terminated

Gastrointestinal Cancer|Digestive System Cancer|Lung Cancer|Esophageal Cancer|Mesothelioma|Breast Cancer

2019-08-20

12-C-0135

P2

Terminated

Sarcoma, Ewing

2014-05-21

Recent News Events

Date

Type

Title